These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21723733)

  • 1. Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors.
    Whitehead L; Dobler MR; Radetich B; Zhu Y; Atadja PW; Claiborne T; Grob JE; McRiner A; Pancost MR; Patnaik A; Shao W; Shultz M; Tichkule R; Tommasi RA; Vash B; Wang P; Stams T
    Bioorg Med Chem; 2011 Aug; 19(15):4626-34. PubMed ID: 21723733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azetidinones as zinc-binding groups to design selective HDAC8 inhibitors.
    Galletti P; Quintavalla A; Ventrici C; Giannini G; Cabri W; Penco S; Gallo G; Vincenti S; Giacomini D
    ChemMedChem; 2009 Dec; 4(12):1991-2001. PubMed ID: 19821480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases.
    Wang DF; Helquist P; Wiech NL; Wiest O
    J Med Chem; 2005 Nov; 48(22):6936-47. PubMed ID: 16250652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inside HDAC with HDAC inhibitors.
    Bertrand P
    Eur J Med Chem; 2010 Jun; 45(6):2095-116. PubMed ID: 20223566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for the design and synthesis of selective HDAC inhibitors.
    Di Micco S; Chini MG; Terracciano S; Bruno I; Riccio R; Bifulco G
    Bioorg Med Chem; 2013 Jul; 21(13):3795-807. PubMed ID: 23693069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docking of hydroxamic acids into HDAC1 and HDAC8: a rationalization of activity trends and selectivities.
    Ortore G; Di Colo F; Martinelli A
    J Chem Inf Model; 2009 Dec; 49(12):2774-85. PubMed ID: 19947584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ligand release mechanisms and channels in histone deacetylases.
    Kalyaanamoorthy S; Chen YP
    J Comput Chem; 2013 Oct; 34(26):2270-83. PubMed ID: 23893931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors.
    Smil DV; Manku S; Chantigny YA; Leit S; Wahhab A; Yan TP; Fournel M; Maroun C; Li Z; Lemieux AM; Nicolescu A; Rahil J; Lefebvre S; Panetta A; Besterman JM; Déziel R
    Bioorg Med Chem Lett; 2009 Feb; 19(3):688-92. PubMed ID: 19111466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring inhibitor release pathways in histone deacetylases using random acceleration molecular dynamics simulations.
    Kalyaanamoorthy S; Chen YP
    J Chem Inf Model; 2012 Feb; 52(2):589-603. PubMed ID: 22263580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural origin of selectivity in class II-selective histone deacetylase inhibitors.
    Estiu G; Greenberg E; Harrison CB; Kwiatkowski NP; Mazitschek R; Bradner JE; Wiest O
    J Med Chem; 2008 May; 51(10):2898-906. PubMed ID: 18412327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design.
    Thangapandian S; John S; Sakkiah S; Lee KW
    Eur J Med Chem; 2010 Oct; 45(10):4409-17. PubMed ID: 20656379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
    Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
    Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases.
    Somoza JR; Skene RJ; Katz BA; Mol C; Ho JD; Jennings AJ; Luong C; Arvai A; Buggy JJ; Chi E; Tang J; Sang BC; Verner E; Wynands R; Leahy EM; Dougan DR; Snell G; Navre M; Knuth MW; Swanson RV; McRee DE; Tari LW
    Structure; 2004 Jul; 12(7):1325-34. PubMed ID: 15242608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors.
    Krennhrubec K; Marshall BL; Hedglin M; Verdin E; Ulrich SM
    Bioorg Med Chem Lett; 2007 May; 17(10):2874-8. PubMed ID: 17346959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
    Pabba C; Gregg BT; Kitchen DB; Chen ZJ; Judkins A
    Bioorg Med Chem Lett; 2011 Jan; 21(1):324-8. PubMed ID: 21109435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and primary activity assay of tripeptidomimetics as histone deacetylase inhibitors with linear linker and branched cap group.
    Zhang Y; Feng J; Jia Y; Xu Y; Liu C; Fang H; Xu W
    Eur J Med Chem; 2011 Nov; 46(11):5387-97. PubMed ID: 21924799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological activity of cyclotetrapeptide analogues of the natural HDAC inhibitor FR235222.
    Terracciano S; Di Micco S; Bifulco G; Gallinari P; Riccio R; Bruno I
    Bioorg Med Chem; 2010 May; 18(9):3252-60. PubMed ID: 20381359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of novel isoxazole-based HDAC inhibitors.
    Conti P; Tamborini L; Pinto A; Sola L; Ettari R; Mercurio C; De Micheli C
    Eur J Med Chem; 2010 Sep; 45(9):4331-8. PubMed ID: 20637529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors: structure-based modeling and isoform-selectivity prediction.
    Silvestri L; Ballante F; Mai A; Marshall GR; Ragno R
    J Chem Inf Model; 2012 Aug; 52(8):2215-35. PubMed ID: 22762501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation on the isoform selectivity of histone deacetylase inhibitors using chemical feature based pharmacophore and docking approaches.
    Zhu Y; Li HF; Lu S; Zheng YX; Wu Z; Tang WF; Zhou X; Lu T
    Eur J Med Chem; 2010 May; 45(5):1777-91. PubMed ID: 20153566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.